Skip to main content
. Author manuscript; available in PMC: 2023 Jul 4.
Published in final edited form as: Mol Pharm. 2022 Apr 29;19(7):2535–2541. doi: 10.1021/acs.molpharmaceut.2c00211

Figure 2.

Figure 2.

A. Radioactive HPLC profiles of 64Cu-NOTA-PEG2Nle-CycMSHhex and 64Cu-NOTA-AocNle-CycMSHhex. B. Specific binding of 64Cu-NOTA-PEG2Nle-CycMSHhex (Cu-64-PEG2) and 64Cu-NOTA-AocNle-CycMSHhex (Cu-64-Aoc) on B16/F10 melanoma cells with (black) and without (white) peptide blockade, respectively.